RTN4 and amyotrophic lateral sclerosis: Current knowledge has also led to the initiations of clinical trials in spinal cord injury (NCT00406016), multiple sclerosis (Ineichen et al., 2017), and ALS in which disease a large phase II trial shows no positive effects of Nogo-A antibodies (Meininger et al., 2014).